Dose Timing of an Angiotensin II Receptor Blocker/Calcium Channel Blocker Combination in Hypertensive Patients With...

Area of Science:

• Cardiology
• Hypertension Research
• Clinical Trials

Background:

• Hypertension and atrial fibrillation (AF) share a known association.
• The role of angiotensin II receptor blockers in preventing organ damage in hypertensive individuals with AF remains debated.
• Paroxysmal AF in hypertensive patients requires effective management strategies.

Purpose of the Study:

• To investigate the impact of telmisartan/amlodipine combination therapy timing on blood pressure (BP) and BP variability.
• To compare morning versus bedtime administration of the combination therapy in hypertensive patients with paroxysmal AF.
• To assess the effect of administration timing on N-terminal pro-brain natriuretic peptide levels.

Main Methods:

• A multicentered, prospective, randomized, open-label clinical trial.
• Utilized ambulatory BP monitoring (ABPM) and home BP measurements.
• Included hypertensive patients diagnosed with paroxysmal atrial fibrillation.

Main Results:

• Significant reductions in 24-hour BP, nighttime BP, preawake BP, and morning BP were observed via ABPM.
• Antihypertensive effects and BP variability reduction were comparable between morning and bedtime administration.
• N-terminal pro-brain natriuretic peptide levels decreased significantly only in the bedtime administration group.

Conclusions:

• Telmisartan/amlodipine combination therapy effectively manages BP and BP variability in hypertensive patients with paroxysmal AF.
• Administration timing did not significantly alter BP-lowering effects or BP variability.
• Further research is warranted to determine if bedtime administration optimizes risk reduction for AF recurrence.